The primary therapeutic domain of Radiesse is structural restoration, addressing volume loss that causes visible signs of aging and certain clinical conditions. Calcium Hydroxylapatite (CaHA) is used in the face to smooth wrinkles and folds, and in the hands to correct volume loss.

The product is commonly used to manage the moderate to severe depletion of soft tissue structure, addressing features such as pronounced nasolabial folds, marionette lines, and diminished facial and jawline contours. It is also relevant for the restoration of hand volume and the clinical management of specific conditions like HIV-associated facial lipoatrophy. This supportive approach contributes to improved contouring and volume.

“The treatment is applied in clinical settings that involve conditions presenting with visible structural changes and tissue depletion.”

Quick Fact: Relief for Volume Depletion

Quick Fact: Relief for Volume Depletion The product provides structural support for age-related soft tissue atrophy, assisting with the maintenance of aesthetic appearance during phases of volume loss.

This supportive application provides a sustained benefit that helps manage the visual manifestations of volume loss.

Radiesse is approved for use exclusively in adult patients. The regulatory documentation classifies patient eligibility into specific groups who are allowed to use the medical device and groups for whom its use is strictly prohibited.

Contraindications (Must Not Use)

Use is contraindicated in patients with a history of severe allergies (such as anaphylaxis) or the presence of multiple severe allergies. Individuals with known bleeding disorders are also strictly excluded. Furthermore, the device must not be used in patients with a known hypersensitivity to any component of the implant material, including lidocaine if using the Radiesse Plus formulation. Treatment must be deferred in persons with active skin inflammation or infection in or near the area to be treated until the condition is fully controlled.

Restricted and Not-Established Use

Age eligibility is strictly defined for adults, with the minimum threshold varying from 18 years (for hand augmentation) to 21 years (for jawline contouring). The safety and effectiveness of this device have not been established for several key populations. This includes pediatric patients (under 18 years of age) and women who are either pregnant or breastfeeding. The safety profile has also not been studied in patients with a known tendency toward keloid formation or hypertrophic scarring.

Interactions with other medicines and products

The official regulatory profile for Radiesse, a non-systemic semi-solid implant, establishes constraints focused on procedural timing and localized effects, rather than systemic pharmacokinetic mechanisms.

Interaction Scope

Regulatory Status of Systemic Interactions: The product's regulatory documents state that no formal studies of interactions with other drugs, substances, or implants have been conducted. This means the labeling does not contain information regarding metabolic interactions, such as those related to CYP enzymes, or any exposure-altering effects that would modify systemic drug concentrations.

Localized Pharmacodynamic Risk: Official labeling identifies a localized pharmacodynamic interaction with medications that can prolong bleeding, which includes specific agents such as aspirin and warfarin. Co-administration of these medicines may result in a greater likelihood of bruising or bleeding at the injection site.

Timing-Based and Procedural Restrictions: Administration is restricted in conjunction with specific dermal procedures. Radiesse should not be administered before the skin has completely healed following treatments that cause an active dermal response, including laser treatment or chemical peeling. This is a restriction intended to mitigate the potential risk of an inflammatory reaction at the implant site.

Interaction-Related Contraindications: The use of the RADIESSE® (+) formulation, which contains lidocaine, carries a component-based contraindication for individuals with a known hypersensitivity to lidocaine or other anesthetics of the amide type.

The mechanism of action for Radiesse involves direct volumetric displacement and subsequent long-term cellular matrix modification in dermal and subdermal tissues.

---

Immediate Biomechanical Effect

Upon introduction into the tissue, the microspheres of calcium hydroxylapatite ( CaHA) serve as a three-dimensional scaffold. The gel vehicle and suspended CaHA particles exert an immediate biophysical effect via simple mass addition, creating a local space-occupying depot. This action temporarily modulates the tissue's structural architecture through extrinsic physical pressure and volume augmentation, an entirely non-molecular interaction.

---

Long-term Neocollagenesis Cascade

Over time, the aqueous carrier gel is absorbed by the surrounding tissue. The remaining CaHA microspheres act as an exogenous matrix that recruits fibroblasts and macrophages. These CaHA particles do not interact with specific cell surface receptors or intracellular enzymes. Instead, the particulate structure and chemical composition induce a controlled, subclinical foreign body reaction within the localized tissue microenvironment.

This cellular response includes the activation of recruited fibroblasts, which initiates a sustained cascade of neocollagenesis. Fibroblasts upregulate the production and secretion of Type I and Type III collagen fibers and elastin. This de novo protein synthesis and subsequent deposition and cross-linking of these fibers around the CaHA scaffold lead to the gradual formation of a new, endogenous connective tissue matrix, resulting in a system-level increase in structural integrity and thickness of the treated tissue plane.

How to Use Radiesse

Radiesse is an injectable, semi-solid implant administered solely via subdermal implantation, deep dermal, and/or subcutaneous injection. The protocol for its use is defined by specific administration guidelines, volume limits, and frequency patterns.

Administration and Dosage Regimen

Usage Entity	Standard Protocol
Route of Administration	Deep Dermal, Subcutaneous, or Supraperiosteal Injection.
Dosing Principle	Volume-to-Effect Dosing: The volume injected is tailored to achieve the desired contour correction, using a 1:1 correction factor, which involves stopping administration before overcorrection.
Preparation	May be diluted with 2% Lidocaine HCl for a final concentration of 0.3% Lidocaine or mixed with 0.9% sterile saline for specific indications.
Needle/Cannula	Requires a small-gauge needle or cannula (e.g., 25 to 27 gauge inner diameter) and slow injection pressure.
Frequency Pattern	A single initial treatment session, followed by subsequent touch-up or re-treatment administered as needed to maintain correction.

Usage Constraints

The product is packaged for single-patient use only and must be administered by a licensed healthcare practitioner utilizing aseptic technique. For hand augmentation, volumes over 3.0 cc per hand in a single session have not been studied in clinical trials. Regarding specific populations, safety and effectiveness have not been established in patients under 18 years of age.

Research evidence / Overview of studies for Radiesse

Evidence for Correction of Facial Wrinkles and Contouring

Clinical research examined the assessment of moderate to severe facial wrinkles, folds, and jawline contour loss. Research examined how soft tissue changes over a period of time. Research in this area included randomized, controlled clinical trials (RCTs), where a treated area was compared against a control treatment on the same participant, such as a split-face design. These studies primarily included adults seeking to address visible signs of facial volume depletion.

Studies monitored outcomes measured by validated aesthetic rating scales, such as those that measure wrinkle severity, and the Global Aesthetic Improvement Scale (GAIS). The findings reported in the studies described patterns in assessment scores when tracked in a portion of participants during intermediate and long-term extension phases.

---

Evidence for Hand Volume Correction

Research was evaluated in the context of assessing visible volume change in the dorsum (back) of the hand. This involved multi-center, prospective, randomized, masked, cross-over pivotal clinical studies. The study populations were adults with moderate to severe volume depletion in the hands.

The primary study outcomes examined focused on change in volume assessment scores using validated scales, such as the Merz Hand Grading Scale (MHGS).

---

Long-Term Studies and Durability of Follow-up

While initial pivotal trials often focus on short-term results, research has explored the product's behavior in extension studies to track changes over a longer duration. Clinical reports described patterns observed in facial volume changes that was monitored for extended periods, with some follow-up data showing patterns related to volume assessment scores up to approximately three years after the final injection. This information provides context but not individual predictions regarding the duration of the observed change.

---

Research in Special and Targeted Populations

Research examined individuals with HIV who were experiencing facial fat loss, a condition known as lipoatrophy. The research conducted for this specific indication used open-label clinical trials (non-comparative). The studies monitored outcomes related to physical discomfort and volume assessment. The evidence is limited to the findings from these specific open-label settings and results apply only to the populations studied.

---

Summary of Evidence Limitations and Research Gaps

Limited data are available for certain populations, such as pregnant or breastfeeding patients, and subgroup findings are uncertain in some specific anatomical areas not covered by the original pivotal trials. The current research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References Injectable poly-L-lactic acid and calcium hydroxylapatite: a comparative review of their mechanisms of action and clinical indications

Common questions about Radiesse (FAQ)

Q: Is Radiesse classified as a temporary or long-term treatment?

According to the official product identity, Radiesse is described as a semi-permanent injectable implant. This term indicates that the duration of its observed effects is typically longer than that of temporary dermal fillers.

Q: Where in the body is Radiesse typically used, based on official documents?

Regulatory documents indicate that the product is intended for specific areas. These include the correction of moderate to severe facial wrinkles and folds, deep injection for jawline contour loss, and augmentation to address volume loss in the dorsum (back) of the hands.

Q: How long does the product typically last once administered?

Studies track the product's behavior in extension phases to understand its long-term performance. Clinical follow-up data has described patterns related to volume assessment scores that were monitored for up to approximately three years after the final injection.

Q: Can Radiesse be used while taking common over-the-counter pain relievers?

Official labeling focuses on a localized risk with medications that can prolong bleeding, such as aspirin. The use of blood-thinning medicines may increase the likelihood of bruising or bleeding at the injection site. Formal interaction studies with all over-the-counter pain relievers have not been documented in the regulatory profile.

Q: Is Radiesse ever used in combination with other types of cosmetic treatments?

Official documentation restricts the administration of Radiesse if the skin has not completely healed after treatments that cause an active dermal response, such as laser procedures or chemical peels. This is done to mitigate the risk of an inflammatory reaction at the implant site.

Q: Is Radiesse absorbed by the body over time?

Yes, the product has two main components. The aqueous gel carrier is absorbed by the surrounding tissue over time. The synthetic Calcium Hydroxylapatite (CaHA) microparticles are described as resorbable.

Q: Do package inserts describe any specific preparation required before treatment?

The Instructions for Use describe the technical preparation for the licensed practitioner, such as mixing the product with lidocaine or sterile saline for certain uses. However, specific instructions regarding patient preparation (like dietary restrictions or supplement cessation) before the procedure are not detailed in the public regulatory summaries.

Q: Are the effects of Radiesse reversible, according to research?

The product is classified as an adjustable filler. The new connective tissue that is generated through bio-stimulation around the particles is not fully removed by an active reversal agent, as there is no active reversal agent specified for removing the bio-stimulated tissue.

Q: Is a patch test required before receiving Radiesse, as described in use conditions?

Regulatory documents do not list a mandatory patch test requirement. The device is contraindicated for individuals with a known history of severe allergies or a known hypersensitivity to any component of the implant material.

Q: What is the typical timeframe between treatment sessions, based on official information?

The standard regimen involves a single initial treatment session, followed by subsequent touch-up or re-treatment administered as needed to maintain correction. Regulatory documents do not define a specific typical interval or minimum timeframe between these touch-up sessions.

Q: Can Radiesse be detected on medical imaging, such as X-rays or CT scans?

Yes, the Calcium Hydroxylapatite (CaHA) particles within the product are radiopaque, meaning they can block radiation. Official warnings describe the particles as clearly visible on CT scans and potentially visible in standard plain radiography (X-rays).

Q: Is Radiesse appropriate for all skin types and tones?

Clinical safety studies for hand augmentation indicated that individuals with darker skin tones (Fitzpatrick Skin Types IV–VI) may have a potential for increased risk of temporary difficulty performing activities at the injection site.

Q: Are there any specific lifestyle factors (like sun exposure) that can affect the duration of Radiesse?

Official patient aftercare instructions generally suggest minimizing exposure to extensive sun or heat for approximately 24 hours after treatment or until any initial swelling and redness has completely resolved.

Q: Is the main component of Radiesse naturally found in the body?

The final product is made using synthetic Calcium Hydroxylapatite (CaHA). However, CaHA is a mineral substance chemically identical to that which naturally occurs in human bone and teeth.

Q: What kind of sensation is described during the administration of Radiesse?

The product is often prepared with the anesthetic lidocaine before injection. This preparation indicates that the procedure is associated with the potential for discomfort, which is managed by a numbing agent.

Q: What types of physical trauma or pressure should be avoided after receiving Radiesse?

After treatment, official patient aftercare instructions generally suggest avoiding significant movement or massage of the treated area for approximately 24 hours to allow the implant to settle into the tissue plane.

Q: How should a patient report a side effect related to Radiesse?

The Food and Drug Administration (FDA) provides the MedWatch Online Voluntary Reporting Form (Form FDA 3500B for consumers) for patients and healthcare professionals who wish to report product complaints or adverse events.

Q: How soon after receiving Radiesse can normal daily activities be resumed?

According to official patient aftercare instructions, most usual daily activities can be resumed immediately after treatment. However, intense physical activity or exercise is generally suggested to be avoided for at least 24 hours.

How to Store and Dispose of Radiesse?

The storage and disposal of Radiesse injectable implant must strictly follow official regulatory requirements to maintain product quality and safety.

---

Storage Conditions

Radiesse must be stored at controlled room temperature between 15°C and 32°C (59°F and 90°F). The product is supplied sterile in its original container and must not be frozen or exposed to extreme temperatures. It is intended for single patient use and must not be resterilized.

---

Disposal Instructions

Used syringes and needles are considered potential biohazards. Disposal of both used and unused product must be completed in accordance with accepted medical practice and all applicable local, state, and federal requirements for regulated medical waste. Do not attempt to reshield used needles.